(D) The Director`s decision under subparagraph C(ii) shall be made in writing and the Secretary shall give the sponsor or applicant an opportunity to attend a meeting at which the Director and the sponsor or applicant will be present and at which the Director shall document the relevant scientific matter. (e) Written decisions of the review department shall be binding on the staff of the Field Service or Compliance Unit and may not be modified by them, directly or indirectly, unless the staff of the compliance department or unit explain to the review unit the reasons why the decision should be amended. (F) Action by the examination service shall not be delayed because information provided by field staff is not available or action is taken by field staff, unless the examination service determines that a period of time is necessary to ensure that a safe and effective medicinal product is placed on the market. (G) For the purposes of this paragraph, the examination service shall be the service responsible for examining an application for a marketing authorisation for a medicinal product pursuant to this paragraph or Article 351 of the Public Health Services Act (including all scientific and medical matters, chemistry, manufacturing and controls). (b) Not later than 31. In December of each year, any person who owns or operates an establishment in a State engaged in the manufacture, preparation, multiplication, composition or processing of a drug or device or devices shall register with the Secretary his name, offices and all such establishments. B. A medicinal product or device shall be considered falsified if it claims to be or is represented as a medicinal product whose name is recognized in an official compendium and if its dosage deviates from the standard laid down in this Code or is lower than its quality or purity. This determination of strength, quality or purity shall be carried out in accordance with the tests or test methods set out in this Code or, if such tests or test methods are absent or inadequate, in accordance with those prescribed by federal law. No medicinal product defined in an official compendium shall be considered falsified under this subsection because it deviates from the standard of strength, quality or purity set out in this compendium if the difference in strength, quality or purity from that standard is clearly indicated on the label. (c) DISTRIBUTION. Where possible, the secretary shall distribute information about discontinuation of the medications described in paragraph (a) to appropriate physician and patient organizations. (B) SECRETARY RESPONSIBLE FOR DRAWING UP A LIST OF MEDICINAL PRODUCTS FOR WHICH ADDITIONAL PAEDIATRIC INFORMATION MAY BE USEFUL.

No later than 180 days after the Food and Drug Administration Modernization Act of 1997 comes into force, the Secretary, after consultation with experts in pediatric research, shall develop, prioritize and publish an initial list of approved drugs for which additional pediatric information may have beneficial effects on the health of the pediatric population. The secretary updates the list annually. (c) 1. No person may sell, buy or exchange samples of drugs or offer to sell, buy or exchange them. For the purposes of this paragraph and paragraph (d), “drug sample” means a unit of a drug referred to in paragraph (b) that is not intended for sale and that is intended to promote the sale of the drug. Nothing in this subsection shall subject an officer or officer of a manufacturer or distributor of medicinal products to criminal liability solely for any sale, purchase, exchange or offer to sell, purchase or exchange in violation of this paragraph by other employees of the manufacturer or distributor. (2) No person shall sell, buy or exchange, offer for sale, buy, exchange or counterfeit a voucher. For the purposes of this paragraph, `coupon` means a form which can be exchanged free of charge or at low cost for a medicinal product prescribed in accordance with point (b). (3) No person shall sell, buy or exchange drugs or offer for sale, purchase or trafficke. (k) (1) In the case of a drug for which an authorization for an application under clause (b) or (j) is in effect, the applicant shall prepare and maintain those records and submit those reports to the Secretary. clinical experience data and other data or information received or otherwise obtained by the applicant in relation to that drug, such as the Secretary may require by general order or regulation in connection with such application, based on the determination that such records and reports are necessary for the Secretary to determine: or facilitate the determination of whether there is or may be a reason for invoking the paragraph or paragraphs of this article. Orders made under this subsection and subdivision (i) shall have due regard to the ethics of the medical profession and the interests of patients and, if the Secretary considers it appropriate, shall, at the request of the persons to whom such regulations or orders apply, provide for the consideration of similar information received or otherwise received by the Secretary.

(2) Every person required to keep records under this section and every person in charge or under custody shall, at the request of an officer or employee designated by the secretary, grant the officer or employee access, copy and review of those records. 4. The Regulation referred to in paragraph 1 provides that such an exemption is subject to the condition that the manufacturer or study sponsor requires experts using those medicinal products for testing purposes to certify to the manufacturer or sponsor that they inform all persons to whom those medicinal products or the controls used in them are administered. or their representatives that the drugs are being used for research purposes and obtain the consent of those persons or their representatives, unless this is impossible or contrary to the best interests of those persons.